Collplant announces early development program of antiviral agent for potential treatment of covid-19 patients

Rehovot, israel, nov. 10, 2020 /prnewswire/ -- collplant (nasdaq: clgn) a regenerative medicine company, today announced its development program of an antiviral agent for potential treatment of covid-19 patients. in-vitro early results of collplant's formulations showed significant...
CLGN Ratings Summary
CLGN Quant Ranking